Scipher uses artificial intelligence (AI) and molecular data from patients to discover potential new treatments for autoimmune diseases. Inflammatory diseases in the intestines are also part of this.
Galapagos will provide the US company with an upfront amount as part of the partnership as well as several potential opt-in and milestone payments. In turn, the company listed on the Amsterdam Stock Exchange will acquire the rights to discover, develop and commercialize the therapies based on the currently selected potential drugs.
The most important financial news every morning.
Invalid email address. Please fill in again.